The SABE belle BIOMALIFE® BUTIRBIOMA tablets are a dietary supplement based on sodium butyrate. Each tablet contains 625 mg of modified-release sodium butyrate.
€24.70
Content:
30 Stück
(€0.82 / 1 Stück)
(May vary by country)
Available, delivery time: 1-3 days ⁴
Product number:
RA8078243
Stück:
Manufacturer:
SABE belle
Product information "SABE belle BIOMALIFE® BUTIRBIOMA enteric coated tablets"
SABE belle BIOMALIFE® BUTIRBIOMA tablets – a food supplement based on sodium butyrate. Each tablet contains 625 mg of sodium butyrate with modified-release technology.
The intestinal barrier
- The intestinal barrier is the largest interface and contact surface between our body and the outside world. It acts as an extremely precise, active filter and protective mechanism, distinguishing between nutrients and beneficial substances on the one hand, and potentially harmful antigens and microorganisms on the other. At the heart of the intestinal barrier is the epithelium. This consists of intestinal cells that are firmly bound together by tight junctions, and the protective mucus layer that covers and protects these cells.
- Various factors can damage the intestinal barrier: the protective mucus layer becomes thinner and, in places, is absent or disrupted; the tight junctions open up, creating gaps between the cells (leaky gut syndrome).
- These gaps allow antigens, toxins and bacteria to penetrate the intestinal barrier and enter the gut-associated lymphoid tissue (GALT). The GALT reacts to these foreign substances and activates immune cells, which secrete pro-inflammatory substances. This inflammation of the gut exacerbates the existing disruption of the gut barrier, creating a vicious circle.
Active ingredients
Sodium butyrate is the sodium salt of butyric acid, a short-chain fatty acid produced during the microbial fermentation of dietary fibre in the gut. Butyrate is the preferred source of nutrition and energy for the cells that form the intestinal barrier.
It has a dual effect:
- it helps maintain the intestinal barrier by acting on the tight junctions that hold the intestinal cells together;
- it stimulates the production of mucus, which coats and protects the intestinal cells.
Indications
- IBS – Irritable Bowel Syndrome (with constipation, diarrhoea, or alternating bowel movements)
- IBD – Crohn’s disease and ulcerative colitis
- Diverticular disease
- Coeliac disease
- Recurrent diarrhoea
- Traveller’s diarrhoea
- Food intolerances
- Pharmacological treatments (for the prevention of diarrhoea)
- Flatulence and bowel discomfort (following a course of antibiotics)
- Discomfort following a colonoscopy (2 tablets daily for 1 week beforehand & 1 tablet daily for 1 week afterwards)
- Recurrent Candida infections
Notes
- Gluten-free
- Naturally lactose-free
- No sweeteners
- No added sugar
- No preservatives
• M. Cuff, J. Dyer, M. Jones et al, ‘The human colonic monocarboxylate transporter Isoform 1: its potential importance to colonic tissue homeostasis’, Gastroenterology, vol. 128, no. 3, pp. 676–686, 2005. • C. Kelly, L. Zheng, E. Campbell et al, ‘Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function,’ *Cell Host & Microbe*, vol. 17, no. 5, pp. 662–671, 2015. • A. Dilly, Y. Lee, H. Zeh et al, ‘Targeting Hypoxia-Mediated Mucin 2 Production as a Therapeutic Strategy for Mucinous Tumours’, Transl Res, vol. 169, pp. 19–30, 2016. • L. Peng, Z. Li, R. Green et al, ‘Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers’, J Nutr, vol. 139, pp. 1619–1625, 2009. • T. Banasiewicz, E. Kaczmarek, J. Maik et al, ‘Quality of life and clinical symptoms in patients with irritable bowel syndrome receiving complementary treatment with protected sodium butyrate,’ Gastroenterol Prakt, vol. 5, pp. 45–53, 2011. • T. Banasiewicz, E. Kaczmarek, J. Maik et al, ‘The influence of protected sodium butyrate on the frequency and severity of certain clinical symptoms in patients with irritable bowel syndrome’, Gastroenterol Prakt, vol. 1, pp. 16–23, 2012. • E. Scarpellini, E. Lauritano, A. Lupascu et al., ‘Efficacy of butyrate in the treatment of diarrhoea-predominant irritable bowel syndrome’, Dig Liver Dis, pp. 19–22, 2007. • W. Tarnowski, K. Borycka-Kiciak, A. Kiciak et al., ‘Outcome of treatment with butyric acid in irritable bowel syndrome – preliminary report’, Gastroenterol Prakt, vol. 1, pp. 43–48, 2011. • L. Krokowicz, Z. Stojcev, B. Kaczmarek et al, ‘Microencapsulated sodium butyrate administered to patients with diverticulosis decreases the incidence of the condition,’ Int J Colorectal Dis, vol. 29, no. 3, pp. 387–393, 2014.
Dosage form
Enteric-coated tablets
Directions for use
- Take up to 3 tablets daily, preferably with a meal, with a little water. The product may be taken for several months.
- Notes: Suitable for children aged 6 years and over. Safe during pregnancy and whilst breastfeeding. The tablets must not be crushed or ground up, but must be swallowed whole.
Ingredients
- Ingredients: SODIUM BUTYRATE, STABILISER: HYDROXYPROPYLMETHYLCELLULOSE; ACIDITY REGULATOR: CALCIUM CARBONATE; COATING AGENTS: ETHYL CELLULOSE, HYDROXYPROPYL CELLULOSE, TALC, SODIUM ALGINATE, MEDIUM-CHAIN TRIGLYCERIDES, POLYETHYLENE GLYCOL, FATTY ACIDS; FIRMING AGENT: SORBITOL; ACIDITY REGULATOR: CALCIUM HYDROXIDE; MAIZE STARCH; ANTI-CAKING AGENTS: CALCIUM SALTS OF FATTY ACIDS, SILICA; COLOURING AGENT: CALCIUM CARBONATE; THICKENING AGENTS: GUAR GUM, SODIUM ALGINATE.
- Composition per 1 tablet: sodium butyrate 625 mg of which butyrate 500 mg.
| Gluten-free: | Yes |
|---|---|
| Lactose-free: | Yes |
| Piece: | 30 |
| Vegetarian: | Yes |
Read more
No reviews found. Share your insights with others.
Warnings - SABE belle BIOMALIFE® BUTIRBIOMA enteric coated tablets
Instructions for use
Product recommendations for you